|
Daehan Nupharm Reports KRW 104.4 Billion in Q2 Sales, Up 8.6% Year-on-Year
2023.08.14
|
|---|
|
Daehan Nupharm announced that its sales for the first half of 2023 reached KRW 104.4 billion, an 8.6% increase compared to the same period last year. Operating profit was recorded at KRW 12.9 billion. Income before income taxes came to KRW 14.8 billion, and net income was KRW 10.9 billion, representing a decrease of 25.5% and 27.1%, respectively, year-on-year. However, excluding the KRW 8.9 billion reversal of litigation provisions recorded in the previous year, income before income taxes from continuing operations was KRW 10.9 billion and net income was KRW 8.1 billion, reflecting a 35.2% and 32.2% increase compared to the same period last year.
|


Home